Health Technology Holding (HTH)

HTH (Health Technology Holding) is a Milan-based venture capital firm specializing in investments within the life sciences sector. Established in 2020 as part of ZCube-Zambon Research Venture, HTH focuses on backing early-stage deep tech startups dedicated to improving human health. The firm’s investment strategy spans a broad range of verticals, including biotech, medtech, digital health, femtech, diagnostics, and consumer healthcare. HTH is particularly interested in companies leveraging cutting-edge technologies such as AI, advanced biotech, and novel medical devices that address unmet needs in healthcare. Their portfolio includes pioneering companies like SOM Biotech, which uses AI to repurpose existing drugs, and Neurofenix, a platform that aids in neurological rehabilitation through innovative sensor technology. The team at HTH is composed of experts from various scientific and technical backgrounds, including statisticians, pharmacists, and biotechnologists. This diverse expertise allows them to provide not only capital but also strategic guidance to their portfolio companies. They focus on fostering innovation that has the potential to make a significant impact on global health, with a special emphasis on scalable and sustainable solutions. HTH’s investments typically range from early to mid-stage companies, reflecting their commitment to nurturing breakthrough innovations from the ground up. The firm also actively collaborates with a wide network of healthcare companies and partners to drive the development and commercialization of transformative health technologies.